Father of Pharmacogenetics Dies

Arno Motulsky, a former refugee from Nazi Germany and a pioneering medical geneticist at the University of Washington, has died at age 94.

Jan 31, 2018
Catherine Offord

CLARE MCLEAN/UW MEDICINEArno Motulsky, a pioneer of medical genetics at the University of Washington, died earlier this month (January 17) surrounded by his children. He was 94.

Among his many contributions to science, Motulsky is credited with founding the field of pharmacogenetics—the study of genetic influences on drug response. “The relationship between heredity and the response to drug therapy—nobody was thinking about that until he started, 60 years ago,” Francis Collins, director of the National Institutes of Health, tells The New York Times. “He anticipated it decades before science made it possible to get the answers that he dreamed of.”

Born into a Jewish family in the summer of 1923 in East Prussia, Motulsky was forced to flee an increasingly hostile Nazi rule at the age of 16. After a boat carrying him and other Jewish refugees was refused entry at both Cuba and the U.S., he returned to Europe, where he was arrested in Belgium and separated from his family. After spending months in internment camps in France, Motulsky sailed to America again in 1941—this time, he was able to obtain US citizenship and was reunited with his father, and later his mother and siblings.

In 1947, Motulsky graduated from the University of Illinois with an MD, and, following several residencies, accepted a faculty position at the University of Washington in Seattle in 1953. It was here, a few years later, that he would open one of the country’s first divisions of medical genetics, drawing an early link between genetic research and the potential to tailor medicine to individual patients. “The field is now integrated into every other field of medical practice, and has become the soul of precision medicine,” University of Washington geneticist Mary Claire King tells The New York Times.

During his tenure, Motulsky applied his research to various medical problems, including blood disorders, colorblindness, and alcoholism. One of his most cited studies, with more than 5,000 mentions since it was published in JAMA in 1995, drew a link between blood levels of the amino acid homocysteine and risk of heart disease, along with potential medical countermeasures. Speaking to The Scientist in 1997, Motulsky attributed the paper’s popularity to “the importance of the problem, the showing quite clearly of a somewhat novel risk factor, and, most excitingly, the possibility of being able to do something about [it].” 

In addition to research contributions over his 60-year career, Motulsky played an active role in science policy and advocacy, helping to found what is now the National Academy of Medicine and acting as an advisor to the World Health Organization, the National Research Council, and the President’s Commission on Bioethics, among other organizations. His awards include the Alexander von Humboldt Award and a Lifetime Achievement Award from the American College of Medical Genetics and Genomics.

Considered a talented teacher and mentor by colleagues and students, Motulsky continued to take part in scientific discourse at the University of Washington well into his 90s. “He was always willing to offer sage advice and always current with the scientific literature,” Gail Jarvik, a University of Washington professor, says in a statement. “Fittingly, on his last day at the University, he attended the seminar of a former trainee, and asked an insightful question.”

Writing an invited autobiography for the Annual Review of Genomics and Human Genetics in 2016, Motulsky described the last 70 years of his career as “a great adventure.”

“I came both to America and to human genetics by a circuitous and ultimately very fortunate route,” he said. “I hope the next generation of geneticists will enjoy reading about it.”

Motulsky is survived by three children, six grandchildren, and two great grandchildren.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.